The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...
The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...
High-dose cholecalciferol (vitamin D) is safe and can nearly double the time it takes for clinically isolated syndrome to ...
TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...
Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...
AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - FR0010557264 - ...
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...
MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.
ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.
Data underscore the potential to leverage comprehensive epigenomic profiling from a simple blood test to explore central nervous system disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback